

Albert C Koong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2310120/publications.pdf>

Version: 2024-02-01

279
papers

20,532
citations

8749

75
h-index

11601

135
g-index

287
all docs

287
docs citations

287
times ranked

24031
citing authors

#	ARTICLE	IF	CITATIONS
1	Implementation and Assessment of an Informal Virtual Elective for Medical Student Radiation Oncology Exploration During the COVID19 Pandemic: a Brief Report. <i>Journal of Cancer Education</i> , 2023, 38, 344-348.	0.6	1
2	Gastrointestinal malignancies and supportive care trials: a snapshot of the last two decades. <i>BMJ Supportive and Palliative Care</i> , 2022, 12, 42-45.	0.8	2
3	Design and validation of a synchrotron proton beam line for FLASH radiotherapy preclinical research experiments. <i>Medical Physics</i> , 2022, 49, 497-509.	1.6	16
4	Intraoperative Radiation After Pelvic Short Course Radiation-Based Total Neoadjuvant Therapy for Patients With Rectal Adenocarcinoma at High Risk for Local Recurrence. <i>Clinical Colorectal Cancer</i> , 2022, 21, 204-211.	1.0	1
5	Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. <i>Cancer Immunology Research</i> , 2022, 10, 259-271.	1.6	10
6	Stress-induced tyrosine phosphorylation of RtcB modulates IRE1 activity and signaling outputs. <i>Life Science Alliance</i> , 2022, 5, e202201379.	1.3	8
7	Patient, physician, and policy factors underlying variation in use of telemedicine for radiation oncology cancer care. <i>Cancer Medicine</i> , 2022, , .	1.3	6
8	Contemporary use and outcomes of radiation and chemotherapy for unresectable pancreatic cancer. <i>Clinical and Translational Radiation Oncology</i> , 2022, 35, 9-16.	0.9	2
9	Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 1901.	1.7	15
10	Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. <i>Cancer</i> , 2022, 128, 2529-2539.	2.0	7
11	Patient-Reported Bowel and Urinary Function in Long-Term Survivors of Squamous Cell Carcinoma of the Anus Treated With Definitive Intensity Modulated Radiation Therapy And Concurrent Chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 78-88.	0.4	8
12	Health Care Resource Utilization for Esophageal Cancer Using Proton versus Photon Radiation Therapy. <i>International Journal of Particle Therapy</i> , 2022, 9, 18-27.	0.9	1
13	Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1069-1081.	3.2	75
14	Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer. <i>Advances in Radiation Oncology</i> , 2021, 6, 100621.	0.6	10
15	Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 57-69.	1.8	21
16	Implementation of a stereotactic body radiotherapy program for unresectable pancreatic cancer in an integrated community academic radiation oncology satellite network. <i>Clinical and Translational Radiation Oncology</i> , 2021, 27, 147-151.	0.9	0
17	Effectively Conducting Oncology Clinical Trials During the COVID-19 Pandemic. <i>Advances in Radiation Oncology</i> , 2021, 6, 100676.	0.6	7
18	Dosimetric Uncertainties Resulting From Interfractional Anatomic Variations for Patients Receiving Pancreas Stereotactic Body Radiation Therapy and Cone Beam Computed Tomography Image Guidance. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1298-1309.	0.4	12

#	ARTICLE	IF	CITATIONS
19	A Machine Learning Model Approach to Risk-Stratify Patients With Gastrointestinal Cancer for Hospitalization and Mortality Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 135-142.	0.4	8
20	Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era. <i>Advances in Radiation Oncology</i> , 2021, 6, 100763.	0.6	19
21	Radiotherapy clinical trial enrollment during the COVID-19 pandemic. <i>Acta Oncologica</i> , 2021, 60, 312-315.	0.8	8
22	Prognostic impact of lymphopenia and neutrophil-lymphocyte ratio for patients with anal squamous cell carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2412-2422.	0.6	4
23	Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, , .	1.0	0
24	Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3773-3777.	0.8	17
25	Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma. <i>Journal of Personalized Medicine</i> , 2021, 11, 1270.	1.1	3
26	Automated hepatobiliary toxicity prediction after liver stereotactic body radiation therapy with deep learning-based portal vein segmentation. <i>Neurocomputing</i> , 2020, 392, 181-188.	3.5	6
27	Predicting Survival for Patients With Metastatic Disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 52-60.	0.4	18
28	IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer. <i>Advances in Radiation Oncology</i> , 2020, 5, 369-376.	0.6	5
29	Radiation Oncology Strategies to Flatten the Curve During the Coronavirus Disease 2019 (COVID-19) Pandemic: Experience From a Large Tertiary Cancer Center. <i>Advances in Radiation Oncology</i> , 2020, 5, 567-572.	0.6	12
30	Intensified systemic therapy and stereotactic ablative radiotherapy dose for patients with unresectable pancreatic adenocarcinoma. <i>Radiotherapy and Oncology</i> , 2020, 152, 63-69.	0.3	19
31	Telemedicine for Radiation Oncology in a Post-COVID World. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 407-410.	0.4	21
32	Understanding the Intersection of Working from Home and Burnout to Optimize Post-COVID19 Work Arrangements in Radiation Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 370-373.	0.4	35
33	Abdominal FLASH irradiation reduces radiation-induced gastrointestinal toxicity for the treatment of ovarian cancer in mice. <i>Scientific Reports</i> , 2020, 10, 21600.	1.6	119
34	Mitigating the impact of COVID-19 on oncology: Clinical and operational lessons from a prospective radiation oncology cohort tested for COVID-19. <i>Radiotherapy and Oncology</i> , 2020, 148, 252-257.	0.3	20
35	Radiation for Glioblastoma in the Era of Coronavirus Disease 2019 (COVID-19): Patient Selection and Hypofractionation to Maximize Benefit and Minimize Risk. <i>Advances in Radiation Oncology</i> , 2020, 5, 743-745.	0.6	12
36	Deep learning for identification of critical regions associated with toxicities after liver stereotactic body radiation therapy. <i>Medical Physics</i> , 2020, 47, 3721-3731.	1.6	22

#	ARTICLE	IF	CITATIONS
37	Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1586-1595.	1.1	8
38	Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1569-1579.	0.8	158
39	The Utility of Stereotactic Ablative Radiation Therapy for Palliation of Metastatic Pancreatic Adenocarcinoma. <i>Practical Radiation Oncology</i> , 2020, 10, 274-281.	1.1	8
40	Evaluation of the Visibility and Artifacts of 11 Common Fiducial Markers for Image Guided Stereotactic Body Radiation Therapy in the Abdomen. <i>Practical Radiation Oncology</i> , 2020, 10, 434-442.	1.1	16
41	Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. <i>Cell</i> , 2020, 181, 832-847.e18.	13.5	77
42	Rapid Detection of Asymptomatic Coronavirus Disease 2019 by Computed Tomography Image Guidance for Stereotactic Ablative Radiotherapy. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1085-1087.	0.5	15
43	Induced Tumor Heterogeneity Reveals Factors Informing Radiation and Immunotherapy Combinations. <i>Clinical Cancer Research</i> , 2020, 26, 2972-2985.	3.2	9
44	Pathologic Response and Postoperative Complications After Short-course Radiation Therapy and Chemotherapy for Patients With Rectal Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2020, 19, 116-122.	1.0	1
45	A multi-scale integrated analysis identifies KRT8 as a pan-cancer early biomarker. , 2020, , .		6
46	Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. <i>Genetics in Medicine</i> , 2019, 21, 213-223.	1.1	151
47	Markerless Pancreatic Tumor Target Localization Enabled By Deep Learning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 432-439.	0.4	49
48	Enhancing clinical trial enrollment at MD Anderson Cancer Center satellite community campuses. <i>Acta OncolÃ³gica</i> , 2019, 58, 1135-1137.	0.8	2
49	Assessment of setup uncertainty in hypofractionated liver radiation therapy with a breath-hold technique using automatic image registrationâ€based image guidance. <i>Radiation Oncology</i> , 2019, 14, 154.	1.2	8
50	Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. <i>Practical Radiation Oncology</i> , 2019, 9, 322-332.	1.1	121
51	Definitive hyperfractionated, accelerated proton reirradiation for patients with pelvic malignancies. <i>Clinical and Translational Radiation Oncology</i> , 2019, 19, 59-65.	0.9	17
52	EUS-guided fiducial placement for GI malignancies: a systematic review and meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2019, 89, 659-670.e18.	0.5	33
53	The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy. <i>Radiotherapy and Oncology</i> , 2019, 133, 9-15.	0.3	50
54	Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience. <i>VideoGIE</i> , 2019, 4, 223-225.	0.3	20

#	ARTICLE	IF	CITATIONS
55	Neural Networks for Deep Radiotherapy Dose Analysis and Prediction of Liver SBRT Outcomes. IEEE Journal of Biomedical and Health Informatics, 2019, 23, 1821-1833.	3.9	25
56	Effect of setup and inter-fraction anatomical changes on the accumulated dose in CT-guided breath-hold intensity modulated proton therapy of liver malignancies. Radiotherapy and Oncology, 2019, 134, 101-109.	0.3	11
57	Predicting Pancreatic Cancer Resectability and Outcomes Based on an Objective Quantitative Scoring System. Pancreas, 2019, 48, 622-628.	0.5	12
58	Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance. Journal of Clinical Investigation, 2019, 129, 5553-5567.	3.9	94
59	Preclinical testing of ultra-rapid FLASH total abdominal irradiation demonstrates survival benefit and decreased gastrointestinal toxicity compared to conventional external beam radiation.. Journal of Clinical Oncology, 2019, 37, 3092-3092.	0.8	1
60	Present developments in reaching an international consensus for a model-based approach to particle beam therapy. Journal of Radiation Research, 2018, 59, i72-i76.	0.8	8
61	Breathing New Life Into Hypoxia-Targeted Therapies for Non-Small Cell Lung Cancer. Journal of the National Cancer Institute, 2018, 110, 1-2.	3.0	34
62	18F-EF5 PET-based Imageable Hypoxia Predicts Local Recurrence in Tumors Treated With Highly Conformal Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1183-1192.	0.4	22
63	A Human Genome-Wide RNAi Screen Reveals Diverse Modulators that Mediate IRE1-XBP1 Activation. Molecular Cancer Research, 2018, 16, 745-753.	1.5	8
64	Strategies for prediction and mitigation of radiation-induced liver toxicity. Journal of Radiation Research, 2018, 59, i40-i49.	0.8	33
65	Resectable and Borderline Resectable Pancreatic Cancer. Practical Guides in Radiation Oncology, 2018, , 199-229.	0.0	0
66	High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer. Radiotherapy and Oncology, 2018, 128, 584-590.	0.3	58
67	Management of Borderline Resectable Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1155-1174.	0.4	48
68	Albumin and Neutrophil-Lymphocyte Ratio (NLR) Predict Survival in Patients With Pancreatic Adenocarcinoma Treated With SBRT. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 242-247.	0.6	54
69	Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncology, 2018, 4, e173420.	3.4	155
70	Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 100, 486-489.	0.4	2
71	Hypoxia imaging in upper gastrointestinal tumors and application to radiation therapy. Journal of Gastrointestinal Oncology, 2018, 9, 1044-1053.	0.6	5
72	Dose escalation for locally advanced pancreatic cancer: How high can we go?. Advances in Radiation Oncology, 2018, 3, 693-700.	0.6	30

#	ARTICLE	IF	CITATIONS
73	Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Scientific Reports, 2018, 8, 14008.	1.6	25
74	Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 10756-10761.	3.3	121
75	Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. Cancer Medicine, 2018, 7, 4880-4892.	1.3	23
76	The role of bone marrow and spleen irradiation in the development of acute hematologic toxicity during chemoradiation for esophageal cancer. Advances in Radiation Oncology, 2018, 3, 297-304.	0.6	12
77	Development of deep neural network for individualized hepatobiliary toxicity prediction after liver <scp>SBRT</scp>. Medical Physics, 2018, 45, 4763-4774.	1.6	103
78	Hyperfractionated abdominal reirradiation for gastrointestinal malignancies. Radiation Oncology, 2018, 13, 143.	1.2	9
79	Stereotactic body radiation therapy for adrenal gland metastases: Outcomes and toxicity. Advances in Radiation Oncology, 2018, 3, 621-629.	0.6	38
80	Can looking at density differences between liver parenchyma and oligometastatic lesions predict outcomes and toxicities in patients receiving stereotactic body radiation therapy for metastatectomy?. Journal of Clinical Oncology, 2018, 36, 479-479.	0.8	0
81	Prediction of pancreatic cancer surgical outcomes and prognosis based on an objective resectability scoring system.. Journal of Clinical Oncology, 2018, 36, 446-446.	0.8	57
82	The Prognostic Significance of Pretreatment Hematologic Parameters in Patients Undergoing Resection for Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 405-412.	0.6	46
83	Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer. Practical Radiation Oncology, 2017, 7, 173-182.	1.1	42
84	Hypoxia-Induced Endoplasmic Reticulum Stress. , 2017, , 225-247.		0
85	The Impact of Intensity Modulated Radiation Therapy on Hospitalization Outcomes in the SEER-Medicare Population With Anal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2017, 98, 177-185.	0.4	24
86	Chemical Space Mimicry for Drug Discovery. Journal of Chemical Information and Modeling, 2017, 57, 875-882.	2.5	63
87	Assessing local progression after stereotactic body radiation therapy for unresectable pancreatic adenocarcinoma: CT versus PET. Practical Radiation Oncology, 2017, 7, 120-125.	1.1	6
88	Does radiotherapy still have a role in unresected biliary tract cancer?. Cancer Medicine, 2017, 6, 129-141.	1.3	32
89	Introduction. Seminars in Radiation Oncology, 2017, 27, 189.	1.0	4
90	ACR Appropriateness Criteria® Resectable Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 109-117.	0.6	7

#	ARTICLE	IF	CITATIONS
91	Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study. <i>Radiology</i> , 2017, 283, 460-468.	3.6	36
92	Perfusion CT measurements predict tumor response in rectal carcinoma. <i>Abdominal Radiology</i> , 2017, 42, 1132-1140.	1.0	11
93	Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. <i>British Journal of Cancer</i> , 2017, 117, 1874-1882.	2.9	73
94	A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer. <i>Cancer Cell</i> , 2017, 32, 460-473.e6.	7.7	142
95	Combining deep learning with anatomical analysis for segmentation of the portal vein for liver SBRT planning. <i>Physics in Medicine and Biology</i> , 2017, 62, 8943-8958.	1.6	65
96	Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1028-1061.	2.3	762
97	Radiation Therapy for Hepatocellular Carcinoma: Clinical Data. , 2017, , 179-198.		0
98	BLIMP1 Induces Transient Metastatic Heterogeneity in Pancreatic Cancer. <i>Cancer Discovery</i> , 2017, 7, 1184-1199.	7.7	53
99	Radiation Therapy for Colorectal Liver Metastases. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 240-249.	1.0	1
100	Central liver toxicity after SBRT: An expanded analysis and predictive nomogram. <i>Radiotherapy and Oncology</i> , 2017, 122, 130-136.	0.3	71
101	Inhibition of IRE1 results in decreased scar formation. <i>Wound Repair and Regeneration</i> , 2017, 25, 964-971.	1.5	7
102	Comprehensive Analysis of the Unfolded Protein Response in Breast Cancer Subtypes. <i>JCO Precision Oncology</i> , 2017, 2017, 1-9.	1.5	6
103	Impact of Intensity-Modulated Radiotherapy on Health Care Costs of Patients With Anal Squamous Cell Carcinoma. <i>Journal of Oncology Practice</i> , 2017, 13, e992-e1001.	2.5	8
104	Statin and Metformin Use Prolongs Survival in Patients With Resectable Pancreatic Cancer. <i>Pancreas</i> , 2016, 45, 64-70.	0.5	45
105	Reprogramming the immunological microenvironment through radiation and targeting Axl. <i>Nature Communications</i> , 2016, 7, 13898.	5.8	150
106	Robotic intrafractional US guidance for liver SABR: System design, beam avoidance, and clinical imaging. <i>Medical Physics</i> , 2016, 43, 5951-5963.	1.6	17
107	Quantitative Analysis of 18F-Fluorodeoxyglucose Positron Emission Tomography Identifies Novel Prognostic Imaging Biomarkers in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 102-109.	0.4	44
108	Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer. <i>Practical Radiation Oncology</i> , 2016, 6, 417-424.	1.1	19

#	ARTICLE	IF	CITATIONS
109	Identification of Doxorubicin as an Inhibitor of the IRE1-XBP1 Axis of the Unfolded Protein Response. <i>Scientific Reports</i> , 2016, 6, 33353.	1.6	27
110	A Multimodal Data Analysis Approach for Targeted Drug Discovery Involving Topological Data Analysis (TDA). <i>Advances in Experimental Medicine and Biology</i> , 2016, 899, 253-268.	0.8	3
111	Acridine Derivatives as Inhibitors of the IRE1-XBP1 Pathway Are Cytotoxic to Human Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2055-2065.	1.9	24
112	Measuring the Impact of Microenvironmental Conditions on Mitochondrial Dehydrogenase Activity in Cultured Cells. <i>Advances in Experimental Medicine and Biology</i> , 2016, 899, 113-120.	0.8	2
113	Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies. <i>Journal of Clinical Investigation</i> , 2016, 127, 183-198.	3.9	86
114	A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3. <i>PLoS ONE</i> , 2016, 11, e0147995.	1.1	13
115	ACR Appropriateness Criteria® Local Excision in Early Stage Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 520-525.	0.6	1
116	Low Toxicity in Inflammatory Bowel Disease Patients Treated With Abdominal and Pelvic Radiation Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 564-569.	0.6	25
117	Targeting the IRE1-XBP1 branch of the unfolded protein response in human diseases. <i>Seminars in Cancer Biology</i> , 2015, 33, 48-56.	4.3	142
118	Emerging Treatment Paradigms in Radiation Oncology. <i>Clinical Cancer Research</i> , 2015, 21, 3393-3401.	3.2	33
119	Circulating mRNA Profiling in Esophageal Squamous Cell Carcinoma Identifies FAM84B As A Biomarker In Predicting Pathological Response to Neoadjuvant Chemoradiation. <i>Scientific Reports</i> , 2015, 5, 10291.	1.6	24
120	Comparison of film measurements and Monte Carlo simulations of dose delivered with very high-energy electron beams in a polystyrene phantom. <i>Medical Physics</i> , 2015, 42, 1606-1613.	1.6	40
121	Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 568-576.	0.4	75
122	Treatment Approaches to Locally Advanced Pancreatic Adenocarcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 741-759.	0.9	9
123	Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. <i>Cancer</i> , 2015, 121, 1128-1137.	2.0	447
124	Predictors of Toxicity Associated With Stereotactic Body Radiation Therapy to the Central Hepatobiliary Tract. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 986-994.	0.4	65
125	Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer. <i>Journal of Clinical Pathology</i> , 2015, 68, 341-345.	1.0	37
126	Plant stilbenes induce endoplasmic reticulum stress and their anti-cancer activity can be enhanced by inhibitors of autophagy. <i>Experimental Cell Research</i> , 2015, 339, 147-153.	1.2	25

#	ARTICLE	IF	CITATIONS
127	Serum Transforming Growth Factor- β 1 Change After Neoadjuvant Chemoradiation Therapy Is Associated With Postoperative Pulmonary Complications in Esophageal Cancer Patients Undergoing Combined Modality Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 1023-1031.	0.4	2
128	Multiplex proximity ligation assay to identify a biomarker panel for prognosis in unresectable pancreatic cancer patients treated with stereotactic body radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, , .	0.4	0
129	Stereotactic body radiation therapy and central liver toxicity: A case report. <i>Practical Radiation Oncology</i> , 2015, 5, 282-285.	1.1	11
130	Future of Stereotactic Irradiation – Dose Composition Radiotherapy (DCRT). , 2015, , 239-250.		0
131	Pretreatment lab values to predict overall survival in patients with primary unresectable pancreatic adenocarcinoma treated with SBRT.. <i>Journal of Clinical Oncology</i> , 2015, 33, 433-433.	0.8	0
132	Anal Canal Cancer. <i>Medical Radiology</i> , 2014, , 315-325.	0.0	0
133	Stereotactic body radiation therapy in pancreatic cancer: the new frontier. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1461-1475.	1.1	31
134	Irf1 Has Distinct Catalytic Mechanisms for XBP1/HAC1 Splicing and RIDD. <i>Cell Reports</i> , 2014, 9, 850-858.	2.9	143
135	Postradiotherapy CA19-9 Kinetics Correlate With Outcomes in Patients With Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2014, 43, 777-783.	0.5	1
136	Baseline Metabolic Tumor Volume and Total Lesion Glycolysis Are Associated With Survival Outcomes in Patients With Locally Advanced Pancreatic Cancer Receiving Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 539-546.	0.4	70
137	Lumbosacral spine and marrow cavity modeling of acute hematologic toxicity in patients treated with intensity modulated radiation therapy for squamous cell carcinoma of the anal canal. <i>Practical Radiation Oncology</i> , 2014, 4, 198-206.	1.1	31
138	Stereotactic Body Radiotherapy in the Treatment of Pancreatic Cancer. <i>Seminars in Radiation Oncology</i> , 2014, 24, 140-147.	1.0	50
139	Single- versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 918-925.	0.4	98
140	High Serum Levels of Vascular Endothelial Growth Factor-A and Transforming Growth Factor- β 1 Before Neoadjuvant Chemoradiotherapy Predict Poor Outcomes in Patients with Esophageal Squamous Cell Carcinoma Receiving Combined Modality Therapy. <i>Annals of Surgical Oncology</i> , 2014, 21, 2361-2368.	0.7	21
141	Galectin-1 Mediates Radiation-Related Lymphopenia and Attenuates NSCLC Radiation Response. <i>Clinical Cancer Research</i> , 2014, 20, 5558-5569.	3.2	64
142	False positive 18F-fluorodeoxyglucose positron emission tomography/computed tomography liver lesion mimicking metastasis in 2 patients with gastroesophageal cancer. <i>Practical Radiation Oncology</i> , 2014, 4, 368-371.	1.1	2
143	Stereotactic Body Radiation Therapy: A New Standard Option for Pancreatic Cancer?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1489-1493.	2.3	12
144	Pancreatic Adenocarcinoma, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1083-1093.	2.3	307

#	ARTICLE	IF	CITATIONS
145	Neurotrophic factor GDNF promotes survival of salivary stem cells. <i>Journal of Clinical Investigation</i> , 2014, 124, 3364-3377.	3.9	96
146	FG-3019, a human monoclonal antibody to connective tissue growth factor (CTGF), with gemcitabine/erlotinib (G/E) in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4138-4138.	0.8	6
147	A novel biomarker panel examining response to adjuvant pancreatic cancer therapy in RTOG 9704.. <i>Journal of Clinical Oncology</i> , 2014, 32, 176-176.	0.8	4
148	Outcomes and toxicity of SBRT for patients with unresectable pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 317-317.	0.8	3
149	Pre-SBRT metabolic tumor volume and total lesion glycolysis to predict survival in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 189-189.	0.8	1
150	Clinical deployment of automatic treatment planning for pancreas SBRT patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 219-219.	0.8	0
151	Effects of gemcitabine and stereotactic body radiotherapy on quality of life in locally advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 278-278.	0.8	0
152	A novel biomarker panel examining response to gemcitabine (G) with or without erlotinib (E) for pancreatic cancer (PA) therapy in NCIC clinical trials group PA.3.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4133-4133.	0.8	2
153	ACR Appropriateness Criteria®-Anal Cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2014, 7, 4-14.	0.8	7
154	Impact of Chemotherapy on Normal Tissue Complication Probability Models of Acute Hematologic Toxicity in Patients Receiving Pelvic Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 983-991.	0.4	49
155	The role of adjuvant chemoradiation in the treatment of pancreatic cancer. <i>Journal of Radiation Oncology</i> , 2013, 2, 391-400.	0.7	0
156	Dosimetric Analysis of Organs at Risk During Expiratory Gating in Stereotactic Body Radiation Therapy for Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1090-1095.	0.4	50
157	Safety of 90Y Radioembolization in Patients Who Have Undergone Previous External Beam Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 323-329.	0.4	38
158	Clinical Implementation of Intrafraction Cone Beam Computed Tomography Imaging During Lung Tumor Stereotactic Ablative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 917-923.	0.4	32
159	Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement?. <i>Annals of Surgical Oncology</i> , 2013, 20, 1631-1638.	0.7	25
160	Biomarker Studies on Radiotherapy to Hepatocellular Carcinoma. <i>Oncology</i> , 2013, 84, 64-68.	0.9	10
161	Chemoradiotherapy Before and After Surgery for Locally Advanced Esophageal Cancer: A SEER-Medicare Analysis. <i>Annals of Surgical Oncology</i> , 2013, 20, 3999-4007.	0.7	22
162	Metabolic Tumor Volume Predicts Disease Progression and Survival in Patients with Squamous Cell Carcinoma of the Anal Canal. <i>Journal of Nuclear Medicine</i> , 2013, 54, 27-32.	2.8	51

#	ARTICLE	IF	CITATIONS
163	Cone beam CT imaging with limited angle of projections and prior knowledge for volumetric verification of non-coplanar beam radiation therapy: a proof of concept study. <i>Physics in Medicine and Biology</i> , 2013, 58, 7777-7789.	1.6	6
164	A Novel Aldehyde Dehydrogenase-3 Activator (Alda-89) Protects Submandibular Gland Function from Irradiation without Accelerating Tumor Growth. <i>Clinical Cancer Research</i> , 2013, 19, 4455-4464.	3.2	27
165	Identification and Characterization of a Potent Activator of p53-Independent Cellular Senescence via a Small-Molecule Screen for Modifiers of the Integrated Stress Response. <i>Molecular Pharmacology</i> , 2013, 83, 594-604.	1.0	12
166	First study of onâ€treatment volumetric imaging during respiratory gated VMAT. <i>Medical Physics</i> , 2013, 40, 040701.	1.6	18
167	FG-3019, a human monoclonal antibody to CTGF, with gemcitabine/erlotinib in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 213-213.	0.8	5
168	Association of low serum levels of transforming growth factor Î²1 (TGF-Î²1) and high levels of vascular endothelial growth factor-A (VEGF-A) following neoadjuvant chemoradiotherapy with poor outcome in esophageal cancer patients receiving combined modality therapy: A preliminary analysis using proximity ligation assay.. <i>Journal of Clinical Oncology</i> , 2013, 31, 80-80.	0.8	1
169	Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 343-51.	0.6	55
170	Positron Emission Tomography for Predicting Pathologic Response After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 334-339.	0.6	24
171	Pancreatic Adenocarcinoma, Version 2.2012. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 703-713.	2.3	248
172	Antiangiogenic and Radiation Therapy. <i>Investigative Radiology</i> , 2012, 47, 25-32.	3.5	40
173	BRAF-mutated, Microsatellite-stable Adenocarcinoma of the Proximal Colon. <i>American Journal of Surgical Pathology</i> , 2012, 36, 744-752.	2.1	161
174	Orthovoltage Intraoperative Radiotherapy for Locally Advanced and Recurrent Colorectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2012, 55, 695-702.	0.7	12
175	Evaluation of the geometric accuracy of surrogateâ€based gated VMAT using intrafraction kilovoltage xâ€ray images. <i>Medical Physics</i> , 2012, 39, 2686-2693.	1.6	35
176	ER stressâ€mediated autophagy promotes Myc-dependent transformation and tumor growth. <i>Journal of Clinical Investigation</i> , 2012, 122, 4621-4634.	3.9	336
177	Quantitation of Human Papillomavirus DNA in Plasma of Oropharyngeal Carcinoma Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, e351-e358.	0.4	101
178	Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, e595-e601.	0.4	34
179	Postchemoradiotherapy Positron Emission Tomography Predicts Pathologic Response and Survival in Patients With Esophageal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 471-477.	0.4	54
180	Normal Tissue Complication Probability Modeling of Acute Hematologic Toxicity in Patients Treated With Intensity-Modulated Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 700-706.	0.4	81

#	ARTICLE	IF	CITATIONS
181	Intrafraction Verification of Gated RapidArc by Using Beam-Level Kilovoltage X-Ray Images. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, e709-e715.	0.4	27
182	Modern Radiation Therapy Techniques for Pancreatic Cancer. <i>Gastroenterology Clinics of North America</i> , 2012, 41, 223-235.	1.0	9
183	Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. <i>Modern Pathology</i> , 2012, 25, 1128-1139.	2.9	250
184	Combined Modality Therapy for Rectal Cancer: The Relative Value of Posttreatment Versus Pretreatment CEA as a Prognostic Marker for Disease Recurrence. <i>Annals of Surgical Oncology</i> , 2012, 19, 2471-2476.	0.7	22
185	ACR Appropriateness Criteria® Resectable Rectal Cancer. <i>Radiation Oncology</i> , 2012, 7, 161.	1.2	21
186	Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer. <i>Cancer</i> , 2012, 118, 1119-1129.	2.0	55
187	A phase II multi-institutional study to evaluate gemcitabine and fractionated stereotactic body radiotherapy for unresectable, locally advanced pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4045-4045.	0.8	3
188	Stereotactic ablative radiotherapy: what's in a name?. <i>Practical Radiation Oncology</i> , 2011, 1, 38-39.	1.1	53
189	Rectal and bladder deformation and displacement during preoperative radiotherapy for rectal cancer: Are current margin guidelines adequate for conformal therapy?. <i>Practical Radiation Oncology</i> , 2011, 1, 85-94.	1.1	19
190	Unfolded Protein Response Regulation in Keloid Cells. <i>Journal of Surgical Research</i> , 2011, 167, 151-157.	0.8	13
191	Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. <i>Blood</i> , 2011, 117, 1311-1314.	0.6	427
192	Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. <i>Cancer</i> , 2011, 117, 3342-3351.	2.0	132
193	Stereotactic body radiotherapy for colorectal liver metastases. <i>Cancer</i> , 2011, 117, 4060-4069.	2.0	265
194	Single-Fraction Stereotactic Body Radiation Therapy and Sequential Gemcitabine for the Treatment of Locally Advanced Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 181-188.	0.4	230
195	Tumor Galectin-1 Mediates Tumor Growth and Metastasis through Regulation of T-Cell Apoptosis. <i>Cancer Research</i> , 2011, 71, 4423-4431.	0.4	110
196	A Novel Aldehyde Dehydrogenase-3 Activator Leads to Adult Salivary Stem Cell Enrichment <i>In Vivo</i> . <i>Clinical Cancer Research</i> , 2011, 17, 7265-7272.	3.2	60
197	Stereotactic Body Radiation Therapy for Gastrointestinal Malignancies. <i>Frontiers of Radiation Therapy and Oncology</i> , 2011, 43, 412-427.	1.4	15
198	Interfractional Uncertainty in the Treatment of Pancreatic Cancer With Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 603-607.	0.4	59

#	ARTICLE	IF	CITATIONS
199	Dose-Escalation Study of Single-Fraction Stereotactic Body Radiotherapy for Liver Malignancies. International Journal of Radiation Oncology Biology Physics, 2010, 78, 486-493.	0.4	279
200	A Dosimetric Model of Duodenal Toxicity After Stereotactic Body Radiotherapy for Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1420-1426.	0.4	143
201	Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. Cancer, 2010, 116, 3943-3952.	2.0	76
202	Expression of p16 ^{INK4A} but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma. Cancer, 2010, 116, 5179-5187.	2.0	16
203	18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1420-1425.	0.4	119
204	Orthovoltage intraoperative radiation therapy for pancreatic adenocarcinoma. Radiation Oncology, 2010, 5, 105.	1.2	7
205	The RGD Domain of Human Osteopontin Promotes Tumor Growth and Metastasis through Activation of Survival Pathways. PLoS ONE, 2010, 5, e9633.	1.1	45
206	Imaging the Unfolded Protein Response in Primary Tumors Reveals Microenvironments with Metabolic Variations that Predict Tumor Growth. Cancer Research, 2010, 70, 78-88.	0.4	90
207	Cetuximab-Based Immunotherapy and Radioimmunotherapy of Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2010, 16, 2095-2105.	3.2	92
208	Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. Translational Oncology, 2010, 3, 109-113.	1.7	285
209	EUS-guided gold fiducial insertion for image-guided radiation therapy of pancreatic cancer: 50 successful cases without fluoroscopy. Gastrointestinal Endoscopy, 2010, 71, 513-518.	0.5	148
210	Cancer of the Pancreas. , 2010, , 801-819.		0
211	Hypoxia Mediated Signaling Pathways. , 2010, , 2241-2245.		0
212	Stereotactic Body Radiation Therapy. , 2010, , 1594-1600.		0
213	Oxygen Consumption Can Regulate the Growth of Tumors, a New Perspective on the Warburg Effect. PLoS ONE, 2009, 4, e7033.	1.1	166
214	Impaired interferon signaling is a common immune defect in human cancer. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9010-9015.	3.3	240
215	The Role of Tumor Cell-Derived Connective Tissue Growth Factor (CTGF/CCN2) in Pancreatic Tumor Growth. Cancer Research, 2009, 69, 775-784.	0.4	129
216	Hypoxia-Induced Lysyl Oxidase Is a Critical Mediator of Bone Marrow Cell Recruitment to Form the Premetastatic Niche. Cancer Cell, 2009, 15, 35-44.	7.7	1,056

#	ARTICLE	IF	CITATIONS
217	Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. <i>Cancer</i> , 2009, 115, 665-672.	2.0	353
218	Pathological Response after Chemoradiation for T3 Rectal Cancer. <i>Colorectal Disease</i> , 2009, 12, e24-30.	0.7	2
219	The Relationship Between Human Papillomavirus Status and Other Molecular Prognostic Markers in Head and Neck Squamous Cell Carcinomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 553-561.	0.4	195
220	Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. <i>Journal of Translational Medicine</i> , 2009, 7, 105.	1.8	50
221	Re: "The safety and efficacy of robotic image-guided radiosurgery system treatment for intra- and extracranial lesions: A systematic review of the literature" [Radiotherapy and Oncology 89 (2009) 245-253]. <i>Radiotherapy and Oncology</i> , 2009, 93, 656-657.	0.3	7
222	Safety and Efficacy of Percutaneous Fiducial Marker Implantation for Image-guided Radiation Therapy. <i>Journal of Vascular and Interventional Radiology</i> , 2009, 20, 235-239.	0.2	174
223	A Primer on Image-guided Radiation Therapy for the Interventional Radiologist. <i>Journal of Vascular and Interventional Radiology</i> , 2009, 20, 859-862.	0.2	10
224	X Box-Binding Protein 1 Regulates Angiogenesis in Human Pancreatic Adenocarcinomas. <i>Translational Oncology</i> , 2009, 2, 31-IN2.	1.7	80
225	Treatment of Esophageal Cancer Based on Histology. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 405-410.	0.6	41
226	Detection of Solitary Humeral Metastasis From Pancreatic Adenocarcinoma With F-18 FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2009, 34, 312-313.	0.7	1
227	Pancreatic Tumor Motion on a Single Planning 4D-CT Does Not Correlate With Intrafraction Tumor Motion During Treatment. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 364-368.	0.6	92
228	Automated Contour Mapping With a Regional Deformable Model. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 599-608.	0.4	30
229	In Vivo 1H Magnetic Resonance Spectroscopy of Lactate in Patients With Stage IV Head and Neck Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1151-1157.	0.4	26
230	Gemcitabine Chemotherapy and Single-Fraction Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 678-686.	0.4	308
231	High-Dose Single-Fraction Radiotherapy: Exploiting a New Biology?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 324-325.	0.4	112
232	Preferential Cytotoxicity of Bortezomib toward Hypoxic Tumor Cells via Overactivation of Endoplasmic Reticulum Stress Pathways. <i>Cancer Research</i> , 2008, 68, 9323-9330.	0.4	126
233	Multiplexed Proximity Ligation Assays to Profile Putative Plasma Biomarkers Relevant to Pancreatic and Ovarian Cancer. <i>Clinical Chemistry</i> , 2008, 54, 582-589.	1.5	84
234	Molecular Imaging of Hypoxia-Inducible Factor 1 α and von Hippel-Lindau Interaction in Mice. <i>Molecular Imaging</i> , 2008, 7, 7290.2008.00017.	0.7	7

#	ARTICLE	IF	CITATIONS
235	Impact of Integrated PET/CT on Variability of Target Volume Delineation in Rectal Cancer. <i>Technology in Cancer Research and Treatment</i> , 2007, 6, 31-36.	0.8	86
236	Amplification of Tumor Hypoxic Responses by Macrophage Migration Inhibitory Factor-Dependent Hypoxia-Inducible Factor Stabilization. <i>Cancer Research</i> , 2007, 67, 186-193.	0.4	94
237	Stereotactic Body Radiotherapy for Unresectable Pancreatic Cancer. <i>Frontiers of Radiation Therapy and Oncology</i> , 2007, 40, 386-394.	1.4	15
238	Enhanced 4D cone-beam CT with interphase motion model. <i>Medical Physics</i> , 2007, 34, 3688-3695.	1.6	105
239	Hypoxia and the Unfolded Protein Response. <i>Methods in Enzymology</i> , 2007, 435, 275-293.	0.4	27
240	Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2007, 29, 211-220.	0.9	80
241	Expression and Prognostic Significance of a Panel of Tissue Hypoxia Markers in Head-and-Neck Squamous Cell Carcinomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 167-175.	0.4	111
242	Multiplexed protein detection by proximity ligation for cancer biomarker validation. <i>Nature Methods</i> , 2007, 4, 327-329.	9.0	169
243	Quantitative PET of EGFR expression in xenograft-bearing mice using ⁶⁴ Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 850-858.	3.3	231
244	CyberKnife Radiosurgery for Pancreatic Cancer. , 2007, , 227-239.		2
245	Comment on: Osteopontin as toxic marker. <i>Radiotherapy and Oncology</i> , 2006, 78, 230.	0.3	2
246	Results of a Phase I Dose-Escalation Study Using Single-Fraction Stereotactic Radiotherapy for Lung Tumors. <i>Journal of Thoracic Oncology</i> , 2006, 1, 802-809.	0.5	98
247	Overview of image-guided radiation therapy. <i>Medical Dosimetry</i> , 2006, 31, 91-112.	0.4	380
248	Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas. <i>Cancer</i> , 2006, 106, 1940-1949.	2.0	54
249	Connective Tissue Growth Factor-Specific Monoclonal Antibody Therapy Inhibits Pancreatic Tumor Growth and Metastasis. <i>Cancer Research</i> , 2006, 66, 5816-5827.	0.4	134
250	Reducing respiratory motion artifacts in positron emission tomography through retrospective stacking. <i>Medical Physics</i> , 2006, 33, 2632-2641.	1.6	51
251	Four-dimensional cone-beam computed tomography using an on-board imager. <i>Medical Physics</i> , 2006, 33, 3825-3833.	1.6	176
252	Targeting XBP-1 as a novel anti-cancer strategy. <i>Cancer Biology and Therapy</i> , 2006, 5, 756-759.	1.5	109

#	ARTICLE	IF	CITATIONS
253	An Evaluation of Tumor Oxygenation and Gene Expression in Patients with Early Stage Non-Small Cell Lung Cancers. <i>Clinical Cancer Research</i> , 2006, 12, 1507-1514.	3.2	237
254	Plasma Osteopontin Is an Independent Prognostic Marker for Head and Neck Cancers. <i>Journal of Clinical Oncology</i> , 2006, 24, 5291-5297.	0.8	61
255	Results of a Phase I Dose-Escalation Study Using Single-Fraction Stereotactic Radiotherapy for Lung Tumors. <i>Journal of Thoracic Oncology</i> , 2006, 1, 802-809.	0.5	193
256	Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 320-323.	0.4	308
257	Identification of Mitogen-Activated Protein Kinase Signaling Pathways That Confer Resistance to Endoplasmic Reticulum Stress in <i>Saccharomyces cerevisiae</i> . <i>Molecular Cancer Research</i> , 2005, 3, 669-677.	1.5	116
258	Galectin-1: A Link Between Tumor Hypoxia and Tumor Immune Privilege. <i>Journal of Clinical Oncology</i> , 2005, 23, 8932-8941.	0.8	233
259	A Noninvasive Approach for Assessing Tumor Hypoxia in Xenografts: Developing a Urinary Marker for Hypoxia. <i>Cancer Research</i> , 2005, 65, 6151-6158.	0.4	10
260	Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. <i>Oncogene</i> , 2005, 24, 6555-6563.	2.6	73
261	The Unfolded Protein Response: A Novel Component of the Hypoxic Stress Response in Tumors. <i>Molecular Cancer Research</i> , 2005, 3, 597-605.	1.5	276
262	The Use of Plasma Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Proteomic Patterns for Detection of Head and Neck Squamous Cell Cancers. <i>Clinical Cancer Research</i> , 2004, 10, 4806-4812.	3.2	72
263	XBP1 Is Essential for Survival under Hypoxic Conditions and Is Required for Tumor Growth. <i>Cancer Research</i> , 2004, 64, 5943-5947.	0.4	496
264	Identification of Hypoxia-Regulated Proteins in Head and Neck Cancer by Proteomic and Tissue Array Profiling. <i>Cancer Research</i> , 2004, 64, 7302-7310.	0.4	36
265	Sample classification from protein mass spectrometry, by 'peak probability contrasts'. <i>Bioinformatics</i> , 2004, 20, 3034-3044.	1.8	196
266	Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 1017-1021.	0.4	420
267	Phase II double-blind randomized study comparing oral aloe vera versus placebo to prevent radiation-related mucositis in patients with head-and-neck neoplasms. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 171-177.	0.4	97
268	Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 132-137.	0.4	134
269	Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 56, 375-383.	0.4	40
270	Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 56, 1046-1054.	0.4	145

#	ARTICLE	IF	CITATIONS
271	Extracranial Radiosurgery Using the CyberKnife. Techniques in Neurosurgery, 2003, 9, 226-231.	0.3	12
272	Hypoxia-Mediated Signaling Pathways. , 2003, , 277-282.		0
273	Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clinical Cancer Research, 2003, 9, 59-67.	3.2	162
274	Pancreatic tumors show high levels of hypoxia. International Journal of Radiation Oncology Biology Physics, 2000, 48, 919-922.	0.4	519
275	Loss of <i>PTEN</i> facilitates HIF-1-mediated gene expression. Genes and Development, 2000, 14, 391-396.	2.7	660
276	Increased cytotoxicity of chronic hypoxic cells by molecular inhibition of GRP78 induction. International Journal of Radiation Oncology Biology Physics, 1994, 28, 661-666.	0.4	75
277	Activators of protein kinase C selectively mediate cellular cytotoxicity to hypoxic cells and not aerobic cells. International Journal of Radiation Oncology Biology Physics, 1994, 29, 259-265.	0.4	13
278	The Regulation of GRP78 and Messenger RNA Levels by Hypoxia Is Modulated by Protein Kinase C Activators and Inhibitors. Radiation Research, 1994, 138, S60.	0.7	39
279	Activation of the heat shock transcription factor by hypoxia in normal and tumor cell lines in vivo and in vitro. International Journal of Radiation Oncology Biology Physics, 1992, 23, 891-897.	0.4	34